Imatinib mesylate induced erythroderma: A rare case report
Journal: IP Indian Journal of Clinical and Experimental Dermatology (IJCED) (Vol.3, No. 2)Publication Date: 2017-06-01
Authors : Snehal Balvant Lunge; Rohan Bhise.;
Page : 88-90
Keywords : Imatinib mesylate; Adverse cutaneous drug reaction; Erythroderma;
Abstract
Imatinib, a specific tyrosine kinase inhibitor is a newer anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is generally well tolerated with few side effects. Most commonly reported adverse events are maculopapular eruptions and periorbital edema. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 55-year-old female who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.
Other Latest Articles
- Evaluation of various chemical peels in facial melanosis
- A clinico-epidemiological profile of HIV positive patients with muco-cutaneous manifestations
- Comparative study of percutaneous collagen induction therapy and dermabrasion on post acne scars
- SYMBOLIC NUMBER IN COSMOLOGY K. PANKOV
- TIME AS AN EXPERIENCE OF THE SOUL ACCORDING TO AURELIUS AUGUSTINE
Last modified: 2017-07-13 17:54:45